Press release
Emerging Sub-Segments Transforming the Atherosclerosis Drugs Market Landscape
Atherosclerosis Drugs Market
Projected Market Size and Growth Outlook for Atherosclerosis Drugs
The atherosclerosis drugs market is anticipated to reach a value of $61.19 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.9%. This steady increase is driven by the expansion of precision medicine tailored to cardiovascular conditions and the growing adoption of digital health monitoring tools that support treatment adherence. Additionally, the demand for combination therapies is rising alongside an aging population, which contributes to the overall market momentum. Innovations in new drug classes targeting atherosclerosis also play a significant role in shaping this growth trajectory. Key trends expected to influence the market include personalized therapy approaches, combination drug formulations, minimally invasive treatment options, preventive cardiovascular healthcare strategies, and the integration of digital patient monitoring systems.
Download a free sample of the atherosclerosis drugs market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Key Factors Fueling Growth in the Atherosclerosis Drugs Market
One major driver behind the expansion of this market is the increasing focus on personalized cardiovascular care. Advances in precision medicine enable treatments tailored specifically to individual patient profiles, improving outcomes and reducing side effects. At the same time, the rise in geriatric populations worldwide creates a larger pool of patients requiring effective atherosclerosis management, thereby boosting demand for innovative drug therapies.
Another critical influence is the growing integration of digital health technologies in cardiovascular care. Remote monitoring tools, mobile health applications, and wearable devices help patients and healthcare providers track treatment progress in real time. This digital shift enhances patient adherence and supports the early detection of complications, thereby improving overall treatment success and expanding the market reach for atherosclerosis drugs.
View the full atherosclerosis drugs market report:
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Players Steering the Atherosclerosis Drugs Market Forward
The competitive landscape of the atherosclerosis drugs sector features numerous prominent pharmaceutical companies including Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co. Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., and Kowa Pharmaceuticals America Inc.
In a notable recent move, Italian pharmaceutical firm Chiesi Farmaceutici S.p.A. acquired Amryt Pharma plc in April 2023 for about $1.25 billion. This acquisition aims to broaden Chiesi's rare disease portfolio, gain access to Amryt's development pipeline, and establish a stronger presence in the US market. Amryt Pharma specializes in developing drugs for rare diseases including atherosclerosis and generalized lipodystrophies, making this acquisition strategically important for expanding treatment options in these areas.
Emerging Trends Shaping the Future of Atherosclerosis Therapies
Research and development efforts in the atherosclerosis drugs market are increasingly focused on novel anti-inflammatory agents designed to address the underlying inflammation that contributes to plaque buildup in arteries. Such drugs have the potential to reduce the risk of severe cardiovascular events and improve long-term patient outcomes.
For example, in June 2023, European medical product company AGEPHA Pharma launched LODOCO, a 0.5 mg colchicine tablet approved by the U.S. FDA as the first anti-inflammatory treatment specifically targeting atherosclerotic cardiovascular disease. LODOCO has demonstrated effectiveness in lowering the risk of heart attacks, strokes, coronary revascularization, and cardiovascular death among adults with atherosclerosis or multiple cardiovascular risk factors. This drug can be used alone or alongside cholesterol-lowering treatments and represents a significant breakthrough in managing residual inflammation associated with atherosclerosis.
Detailed Segment Breakdown of the Atherosclerosis Drugs Market
This market is categorized into several key segments to provide a comprehensive understanding of its scope:
1) By Drug Class:
- Anti-Platelet Medications
- Fibric Acid and Omega-3 Fatty Acid Derivatives
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Diuretics
- Cholesterol Lowering Medications
- Beta Blockers
- Calcium Channel Blockers
- Other Drug Classes
2) By Route of Administration:
- Oral
- Injectable
3) By Distribution Channel:
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Other Distribution Channels
Subcategories of Drug Classes Include:
- Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor
- Fibric Acid and Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements
- ACE Inhibitors: Lisinopril, Enalapril, Ramipril
- Diuretics: Thiazide, Loop, Potassium-Sparing
- Cholesterol Lowering Medications: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants
- Beta Blockers: Metoprolol, Atenolol, Carvedilol
- Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil
- Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors
This segmentation helps highlight the diverse treatment options available in the atherosclerosis drugs market and supports targeted strategies for addressing specific patient needs.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Emerging Sub-Segments Transforming the Atherosclerosis Drugs Market Landscape here
News-ID: 4495344 • Views: …
More Releases from The Business Research Company
Leading Companies Fueling Growth and Innovation in the Tourette Syndrome Market
Understanding the Future Scope of the Tourette Syndrome Market
The market for Tourette syndrome is poised for significant expansion over the coming years. By 2030, it is projected to reach a value of $3.48 billion, growing at a compound annual growth rate (CAGR) of 10.0%. This surge can be linked to several key factors, including increased funding directed toward precision neurology research, advances in personalized treatment strategies, and the…
Outlook on the Autoimmune Gastrointestinal Dysmotility Market: Major Segments, S …
The autoimmune gastrointestinal dysmotility market is positioned for substantial expansion over the coming years. With ongoing advances in diagnosis and treatment, the market is expected to experience notable growth as healthcare providers and patients seek more effective management options for this complex condition. Let's explore the market size forecasts, key players, segmentation, and trends shaping this specialized healthcare sector.
Projected Market Size Growth for the Autoimmune Gastrointestinal Dysmotility Market by 2030…
Global Drivers Analysis: The Rapid Evolution of the Tobramycin Eye Drop Market
The tobramycin eye drop market is set for impressive expansion over the next several years, driven by a range of factors including rising awareness about eye infections and advancements in ophthalmic treatments. This overview explores the market's anticipated growth, leading players, emerging trends, and key segments shaping its future.
Forecasted Expansion of the Tobramycin Eye Drop Market Size
The tobramycin eye drop market is projected to experience substantial growth, reaching…
Market Segmentation, Dynamics, and Competitive Landscape of the Tildrakizumab Ma …
The tildrakizumab market is positioned for strong expansion over the coming years, driven by advancements in autoimmune treatment options and growing investments in immunology research. This forecast highlights how evolving therapeutic strategies and increasing patient focus will shape the market through 2030.
Projected Market Growth Trajectory of the Tildrakizumab Market
The size of the tildrakizumab market is anticipated to climb steadily, reaching $3.02 billion by 2030. This represents a compound…
More Releases for Pharma
Schizophrenia Market: Expanding Revenue Landscape to 2034 - DelveInsight | Teva …
The Key Schizophrenia Companies in the market inlclude - Teva Pharmaceutical Industries, Royalty Pharma, MedinCell, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Lundbeck, Intra-cellular Therapies, Sumitomo Pharma, Otsuka Pharma, Reviva Pharmaceuticals, and others.
DelveInsight's report "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of the Schizophrenia landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
